Closer to Taking Steps

April 2009
PN;Apr2009, Vol. 63 Issue 4, p20
Trade Publication
The article discusses the implication of the approval given by the Food and Drug Administration (FDA) to embryonic-stem-cell trials for Sam Schmidt, a spinal-cord injury (SCI) patient in the U.S. The approval has given Schmidt hopes of being able to return to a normal life. The Sam Schmidt Paralysis Foundation (SSPF) has assisted in funding the first stages of the research on stem cell trials.


Related Articles

  • US stem cell climate improves, raising concerns elsewhere. Siva, Nayanah // Nature Medicine;Mar2009, Vol. 15 Issue 3, p224 

    The article reports that the U.S. Food and Drug Administration (FDA) approved the biotech company Geron Corp. to perform a stem cell trial for people with acute spinal injury. It states that the trial is designed to determine the safety of the stem cell approach to 8-10 paralyzed subjects....

  • Attack of the Clones. Johnson, Alissa // State Legislatures;Apr2003, Vol. 29 Issue 4, p30 

    Provides information on the introduction of state legislatures concerning the use of cloning technology in humans in the U.S. Processes involved in human cloning and therapeutic cloning; Responsibilities of the Food and Drug Administration in regulating reproductive cloning; Sources for...

  • Getting embryonic stem cell therapy right.  // Nature Medicine;May2008, Vol. 14 Issue 5, p467 

    The author reflects on the development of embryonic stem cell therapy for the treatment of wide range of diseases. He cites a meeting hosted by the U.S. Food and Drug Administration to provide a clear guidance on how to regulate clinical trials. He mentions advanced programs outlined by...

  • Forging a Trail to a Cure. Marill, Michele Cohen // Atlanta;Jul2011 Supplement, p6 

    No abstract available.

  • Next Leg in hESC Race. Agres, Ted // Drug Discovery & Development;Mar2009, Vol. 12 Issue 3, p6 

    The article reports on the approval of a clinical trial, which involves a human embryonic stem cell (hESC)-based therapy, by the U.S. Food and Drug Administration (FDA). According to the article, the approval is depicted to be a triumph of science over politics and acclaims a much-needed...

  • Geron Soars as First ESC Trial Clears FDA Hurdle. Boggs, Jennifer // BioWorld Today;1/26/2009, Vol. 20 Issue 15, p1 

    The article reports on the approval of the U.S. Food and Drug Administration (FDA) for the Phase I trial of GRNOPCI, human embryonic stem cells (hESC)-derived oligodendrocytes of Geron Corp. in patients with spinal cord injury. Thomas Okarma, president and chief executive officer of Geron,...

  • Geron Slips on Latest Delay to ESC Trial in Spinal Cord Injury. Boggs, Jennifer // BioWorld Today;8/19/2009, Vol. 20 Issue 159, p1 

    The article reports on the delay in the clinical trial of the human embryonic stem cell-based therapy GRNOPC1 developed by Menlo Park, California-based Geron Corp. It relates that the delay is pending U.S. Food and Drug Administration (FDA) review of recently submitted animal data. It presents...

  • Scalable pluripotent stem cell culture. Couture, Larry A. // Nature Biotechnology;Jun2010, Vol. 28 Issue 6, p562 

    The article discusses the need for culture methods to improve in order to produce human embryonic stem cells (heSCs) in large scale. It states that there have been several developments in heSCs since its upgrade from research laboratories to clinics including the initiation by biotechnology...

  • Stem Cell Study Patients May Need Long-Term Monitoring. Young, Donna // BioWorld Today;4/11/2008, Vol. 19 Issue 71, p1 

    The article focuses on the need for patients involved in studies of cellular therapies derived from human embryonic stem cells (hESCs) to be monitored throughout their lifetime for tumors or other abnormalities, according to the U.S. Food and Drug Administration's Cellular, Tissue and Gene...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics